home / stock / mrzm / mrzm quote
Last: | $0.072 |
---|---|
Change Percent: | 0.0% |
Open: | $0.0735 |
Close: | $0.072 |
High: | $0.0735 |
Low: | $0.072 |
Volume: | 11,000 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.072 | $0.0735 | $0.072 | $0.0735 | $0.072 | 11,000 | 05-03-2024 |
$0.095 | $0.095 | $0.095 | $0.095 | $0.095 | 2,180 | 04-18-2024 |
$0.095 | $0.055 | $0.095 | $0.095 | $0.055 | 26,500 | 04-16-2024 |
$0.055 | $0.0551 | $0.055 | $0.0551 | $0.055 | 26,194 | 04-15-2024 |
$0.0551 | $0.0551 | $0.0551 | $0.0551 | $0.0551 | 2,847 | 04-11-2024 |
$0.055 | $0.055 | $0.055 | $0.055 | $0.055 | 127 | 04-05-2024 |
$0.08843 | $0.08843 | $0.08843 | $0.08843 | $0.08843 | 4,544 | 04-03-2024 |
$0.095 | $0.095 | $0.095 | $0.095 | $0.095 | 127 | 04-01-2024 |
$0.08843 | $0.08843 | $0.08843 | $0.08843 | $0.08843 | 3,000 | 03-27-2024 |
$0.095 | $0.095 | $0.095 | $0.095 | $0.095 | 5,900 | 03-25-2024 |
$0.071 | $0.1339 | $0.071 | $0.1339 | $0.071 | 24,100 | 03-21-2024 |
$0.1 | $0.11 | $0.1 | $0.11 | $0.1 | 6,100 | 03-19-2024 |
$0.095 | $0.095 | $0.095 | $0.095 | $0.095 | 2,000 | 03-18-2024 |
$0.065 | $0.065 | $0.065 | $0.065 | $0.065 | 161 | 03-15-2024 |
$0.065 | $0.065 | $0.065 | $0.065 | $0.065 | 100 | 03-14-2024 |
$0.07 | $0.092 | $0.07 | $0.092 | $0.07 | 10,600 | 03-12-2024 |
$0.1196 | $0.1196 | $0.1196 | $0.1196 | $0.1196 | 9,980 | 03-11-2024 |
$0.1 | $0 | $0.1 | $0 | $0 | 21 | 03-08-2024 |
$0.1 | $0.1 | $0.1 | $0.1 | $0.1 | 9,213 | 03-06-2024 |
$0.1 | $0.1 | $0.1 | $0.1 | $0.1 | 11,446 | 03-04-2024 |
News, Short Squeeze, Breakout and More Instantly...
JUPITER, FL - ( NewMediaWire ) - April 16, 2024 - Marizyme, Inc. ("Marizyme", OTCQB: MRZM) announces today a Co-Development Agreement (the “Agreement”) with Qualigen Therapeutics, Inc. (“Qualigen”) (NASDAQ: QLGN ) to advance the commercial...
--News Direct-- Marizyme Inc CEO David Barthel joined Steve Darling from Proactive to provide an exciting update on the remarkable progress that the company has achieved in recent months. Among the standout developments is the approval received from the US Food and Drug Administration for...
VANCOUVER, BC / ACCESSWIRE / October 13, 2023 / Marizyme, Inc. (OTCQB:MRZM), a global multi-technology biomedical company dedicated to the accelerated development and commercialization of medical technologies that improve patient health outcomes, is featured in today's video by InvestmentPitch M...